they are looking for a HEP B partner or acquisition. ARWR would be a nice fit. Listen to his Lightning Round Recap. He said it. GLTA
CART T Cells science is precise, exact and kills the cancer target with phenominal speed, accuracy, and safety. Yahoooooooooooo
AGIO appears on all accounts to have determined a viable solution. Keep selling you fools I want to get more shares in at a lower price. This is so interesting to follow the action on this stock. There is a true underlying strength here which seems it can't go lower. Besides it also appears AG-120 has great activity on the brain cancers. GLTA
Totally agree. Everyone has a hangup on execs selling. Odd thing is they are prolly gonna buy back before November. They are using market psychology since buffoon investors will exit when the find they are selling. how funny. making $$$ off the very people who freek out. oh well
Manipulators can make big bucks. Oh well just have to go with the flow. GLTA The minute I sell this stock will rocket.
No budging here. hahhahaha
This is another PCYC in the making. Gotta love how manipulators drive this stock. GLTA
But from all accounts this company has the drug, the feel and the instinct that a blockbuster is in the making. It can't hurt to hold my shares until November at least. GLTA
This is a keeper and not selling early no matter what
All hype this week on Calithera Biosciences. No big deal. Let the silly drug CB-839 make its mark. I still prefer AG-120 and the other drugs in AGIO.
The confidence that analysts and even executives at the company display in written articles is awesome for both AML and Glioblastoma patients. It is so thankful the have developed such a noteworthy set of drugs. There wont' be no secondary offer because a large 120 million dollar payment from Celgene will be deposited when the announcement is made in November. How sweet. As follows:
Celgene Corp. (NASDAQ:CELG) holds an option to license ex-U.S. rights after Phase I testing is completed. Agios exercised its option to retain U.S. rights in February. The partners have collaborated to develop cancer metabolism therapies since 2010.
Under the same deal, Celgene took an early option on Agios' AG-221, an inhibitor of mutated isocitrate dehydrogenase 2 (IDH2), during a Phase I trial to treat advanced hematologic malignancies. Under that option, Agios is eligible for $120 million in milestone payments plus tiered royalties (see BioCentury Extra, June 13).
Hold those shares more fun to follow in two months. GLTA
GLTA buy buy buy on those dips until u have the desired quantity.
He believes IDH1 is an important target that has the potential to make a difference for patients with a BROAD RANGE OF HEMATOLOGIC and SOLID Tumor cancers. Remember that when you sell this stock today.
The crop report is in. Buy at the open. Just kidding. It really looks like someone is accumulating. Sit tight this sure looks like its gonna rocket today. AML is a very serious leukemia and someone wants that formula. GLTA
This is a hold til Dec ASCO Conference. The she explodes like PCYC.
hahhahahhahaa GLTA. These three companies need to coordinate this move soon before someone else takes out TGTX. GLTA